January 28, 2017
Swedish Vicore Pharma’s IPF candidate C21 becomes orphan drug in US
Vicore Pharma’s C21 drug for treating idiopathic pulmonary fibrosis (IPF) has officially became an orphan drug in the USA.
Pharmaceuticals, Biotechnology and Life Sciences
Category: North America
January 27, 2017
Roche cancer drug taking bite out of Bristol’s Opdivo
Roche’s cancer drug Tecentriq hit the market months behind immuno-oncology (I/O) medicines from Merck and Bristol-Myers Squibb Co but the Swiss drugmaker’s treatment is making up lost ground.
January 27, 2017
AbbVie’s fourth quarter earnings down, but generates $809M more than 2015 full year
The fourth quarter was a continuation of the strong performance and business momentum AbbVie has delivered since becoming an independent company in 2013.
January 27, 2017
FDA asks Hyland’s teething tablets maker to recall medicines containing belladonna
FDA found that certain teething tablets for children sometimes exceed the amount of belladonna – a toxic substance – and has asked the company that makes them to recall such medicine.
January 27, 2017
BMS posts Q4 net profit, revenues driven by Opdivo sales up
Bristol-Myers Squib on Thursday posted fourth quarter net earnings of $1.1 billion, driven ly by increased sales of Opdivo and Eliquis.
January 26, 2017
BD launches BD Institute for Medication Management Excellence
BD (Becton, Dickinson and Company) has launched its new BD Institute for Medication Management Excellence, developed to help advance the safe and efficient management of medication across the continuum of care.
January 26, 2017
FDA OK’s Ironwood/Allergan’s constipation drug
Ironwood Pharmaceuticals and Allergan have won U.S. Food and Drug Administration’s (FDA) approval for 72 mcg dose of Linzess (linaclotide) for the treatment of chronic idiopathic constipation (CIC) in adult patients.
January 26, 2017
AstraZeneca’s Symbicort for asthma available for 6-12 y.o. children in USA, FDA issues exclusivity rights
AstraZeneca’s Symbicort Inhalation Aerosol is going to be available for 6-12 years old children with asthma in the US
January 25, 2017
Potential Trump FDA Commissioner Choice: A Q&A With Dr. Joseph Gulfo
Here’s a lightly edited version of the interview with Dr. Joseph Gulfo, the executive director of the Lewis Center for Healthcare Innovation and Technology at Fairleigh Dickinson University, the author of “Innovation Breakdown: How the FDA and Wall Street Cripple Medical Advances” and the former President and CEO of the medical device firm MELA Sciences:
January 24, 2017
Probi praises Nutraceutix purchase, announces good Q4 results
Probi, Swedish bioengineering company that develops probiotics has reported Q4 2016 financial results.